Biogen has announced that the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) have started ...
A man with a muscle-wasting disease is pleased Manitoba is asking a federal agency to reconsider its opposition to a ...
More research is needed to confirm gray matter, the darker tissue found in the brain and spinal cord, “as a potential disease ...
Patients with spinal muscular atrophy (SMA) type 2 showed improved motor ability when treated with intrathecal onasemnogene ...
Health activists demand government action to reduce the cost of SMA medicines, citing constitutional obligations and ...
An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines ...
The health activists argue that the government is empowered with effective law and policy tools and therefore should ...
Creatinine, a byproduct of muscle function, may be more sensitive in tracking SMA progression and response to treatment than ...
Application is supported by results from the DEVOTE study, which suggested that two doses of Spinraza (nusinerse) 50 mg taken ...
Scholar Rock aims for a 2025 launch of apitegromab in SMA, expecting $2 billion in global revenue and significant growth from upcoming trials and favorable data.
In a good-news-bad-news week for Biogen, the company will cut an undisclosed number of employees, just as a higher dose of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback